Market Overview

UPDATE: Ascendiant Capital Downgrades Solta Medical to Buy Following Poor Execution

Related SLTM
Benzinga's M&A Chatter for Monday December 16, 2013
Mid-Afternoon Market Update: Markets Rise as Twitter Pulls Back

In a report published Friday, Ascendiant Capital analyst Keay Nakae downgraded the rating on Solta Medical (NASDAQ: SLTM) from Strong Buy to Buy, and lowered the price target from $3.50 to $2.25.

In the report, Nakae noted, “We believe that Solta has now become a ‘show me' stock. While we continue to believe that the Company possesses a nice portfolio of products, which have an attractive recurring revenue component, that leave it well positioned in the aesthetic market, we believe that Management will now need to prove that it can execute the business for a couple of quarters before investors step back in. We are lowering our 12-month price target from $3.50 to $2.25, which represents a target forward EV/EBITDAS multiple of 9.8x our 2014 estimate of $17.5 MM.”

Solta Medical closed on Thursday at $1.87.

Latest Ratings for SLTM

DateFirmActionFromTo
Dec 2013Leerink SwannDowngradesOutperformMarket Perform
Dec 2013Cantor FitzgeraldDowngradesBuyHold
Dec 2013Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for SLTM
View the Latest Analyst Ratings

Posted-In: Ascendiant CapitalAnalyst Color Downgrades Analyst Ratings

 

Related Articles (SLTM)

Around the Web, We're Loving...

Get Benzinga's Newsletters